Desogestrel / Ethinylestradiol: 3 agencies, 2009–2012
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) has been harder on desogestrel / ethinylestradiol than on its own caseload: it refused 3 of 7 decisive submissions here (43%), against a base rate of 11% across everything it has assessed.
The record spans 3.3 years, opening at HAS (France) on 27 May 2009 and running to 19 Sep 2012.
HAS (France) changed its position: recommended on 27 May 2009, not recommended by 19 Sep 2012.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for desogestrel / ethinylestradiol at all.
Nothing has been added since 2012; on this evidence the file is dormant.
HAS (France) was first to assess desogestrel / ethinylestradiol, on 27 May 2009; AWMSG (Wales) did not open a file until 13 Apr 2011 — a moderate spread of 1.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 4 years in total.
2 of the 3 agencies here assessed desogestrel / ethinylestradiol more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed desogestrel / ethinylestradiol.
The full ledger for desogestrel / ethinylestradiol reads 5 recommended, 3 not recommended and 2 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 19 Sep 2012 | Re-assessment of SMR | SMR insufficient | source |
| HAS (France) | 19 Sep 2012 | Re-assessment of SMR | SMR insufficient | source |
| HAS (France) | 19 Sep 2012 | Re-assessment of SMR | SMR insufficient | source |
| AWMSG (Wales) | 13 Apr 2011 | Oral contraception | outside AWMSG criteria | source |
| SMC (Scotland) | 11 Oct 2010 | Oral contraceptive | accepted | source |
5 further decisions for desogestrel / ethinylestradiol, across 2 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- levonorgestrel — same ATC class G03A — Sex hormones and modulators
- desogestrel — same ATC class G03A — Sex hormones and modulators
- etonogestrel — same ATC class G03A — Sex hormones and modulators
- medroxyprogesterone — same ATC class G03A — Sex hormones and modulators
- drospirenone — same ATC class G03A — Sex hormones and modulators
- octocog alfa — also decided by HAS in 2012Q3
Coverage: 10 decisions for desogestrel / ethinylestradiol from 3 agencies, 2009 to 2012. Data to 7 Sep 2026. ATC class G03A — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.